Harvey Berger, a veteran biotech entrepreneur, is returning as CEO of Boston startup Kojin Therapeutics. The company, founded in 2019, is developing pills based on ferroptosis biology to treat a wide range of diseases. Ferroptosis, an iron-dependent form of cell death, has been linked to various illnesses. Kojin is working on two types of pills: one that can induce ferroptosis to kill cancer cells and another that can block ferroptosis to prevent neurogenerative diseases. With about 15 employees, the company is located in the Seaport district. It has not disclosed its lead drug candidates.
Source link
Biotech veteran Harvey Berger to lead startup Kojin Therapeutics
